ALK Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

ALK Tests Market Report Overview

The ALK Tests market size was valued at $27.3 million in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements within non-small cell lung cancer tumor cells, the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC).

ALK Tests Market Outlook 2023-2023 ($ Million)

Buy The Full Report for More Insights on the ALK Tests Market Forecast
Download a Free Report Sample

The ALK Tests market research report explains the market behavior, which will help identify quantitative market trends within the In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on the ALK Tests market for the year 2020 and beyond. Furthermore, the report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing in-licensing and out-licensing strategies.

ALK Tests Market Segments

The key segments in the ALK Tests market are ALK Tests and Next Generation Sequencing (NGS) Tests. In 2023, the ALK Tests segment dominated the market. The ALK Test is sub-segmented into ALK Immunohistochemistry Tests, ALK In Situ Hybridisation Tests, and ALK Nucleic Acid Amplification Tests (NAATs). Within these, ALK In Situ Hybridisation Tests had the highest market share in 2023.

ALK Tests Market Analysis by Segments, 2023 (%)

Buy The Full Report to Know More About the ALK Tests Market Segments
Download a Free Report Sample

ALK Tests Market Segmentation by Regions

The key regions in the ALK Tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2023, North America dominated the ALK Tests market, and the region is expected to retain its position during the forecast period. The market growth can be attributed to a rise in ALK testing owing to increasing lung cancer incidence and steady therapies.

ALK Tests Market Analysis by Regions, 2023 (%)

Buy the Full Report for More Regional Insights into the ALK Tests Market
Download a Free Report Sample

ALK Tests Market – Competitive Landscape

A few of the key companies in the ALK Tests market are:

• Abbott Laboratories
• Qiagen NV
• Agilent Technologies Inc
• Biocare Medical LLC
• Thermo Fisher Scientific Inc

In 2023, Abbott Laboratories accounted for the highest ALK Tests market share, followed by Qiagen NV.

ALK Tests Market Analysis by Companies, 2023 (%)

Buy the Full Report for More Company Insights into the ALK Tests Market
Download a Free Report Sample

Segments Covered in this Report

ALK Tests Segment Outlook ($ Million, 2015-2033)

• ALK Tests
• Next Generation Sequencing (NGS) Tests

ALK Tests Regional Outlook ($ Million, 2015-2033)

• Asia-Pacific
• Europe
• Middle East and Africa
• North America
• South and Central America

Key Inclusions of the market model are:

Currently marketed ALK Tests market and evolving competitive landscape –

• Insightful review of the key industry trends.
• Annualized total ALK Tests market revenue by segment and market outlooks from 2015-2033.
• Market-level data on units, average selling prices, and market values.

Global, Regional, and Country level market specific insights –

• Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for the ALK Tests market.
• Competitive dynamics insights and trends provided for the ALK Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Danaher Corp, Biocare Medical LLC, Thermo Fisher Scientific Inc, Cancer Diagnostics, Inc., Abbott Laboratories, Sysmex Corp, ZytoVision GmbH, Qiagen NV, Bio-Rad Laboratories Inc, Illumina Inc, New England Biolabs Inc, EntroGen, Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This report provides:

• Insightful review of the key industry trends.
• Annualized total ALK Tests market revenue by segment and market outlooks.
• Market-level data on units, average selling prices, and market values.
• Global, regional, and country-level market-specific insights including qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for the ALK Tests market.
• Competitive dynamics insights and trends provided for the ALK Tests market.
• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Reasons to Buy

The model will enable you to –

• Understand the impact of COVID-19 on ALK Tests.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving ALK Tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ALK Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific ALK Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.